Table 5 Clinical trials of antifibrotic drug in CKD
From: Kidney fibrosis: from mechanisms to therapeutic medicines
Drug | Target | Disease | Phase | Outcome | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
FG-3019 | CTGF | FSGS | 1 | Terminated | NCT00782561 |
Microalbuminuric DKD | 1 | Treatment was well tolerated; Decrease in albuminuria | NCT00102297 | ||
DKD with urine ACR > 200 mg/g | 1 | Unknown | NCT00754143 | ||
Type 2 diabetes and DKD with urine ACR > 200–3000 mg/g | 2 | Terminated early for business purposes | NCT00913393 | ||
RG-012 | miR-21 | Alport syndrome | 1 | Unknown | NCT03373786 |
Bardoxolone methyl | Nrf2 | CKD at risk of rapid progression | 2 | Increase in the eGFR | NCT04702997 |
Patients with advanced CKD and type 2 diabetes | 2 | Increase in the eGFR | NCT00811889 (BEAM study) | ||
CKD patients with type 2 diabetes | 2 | Increase in measured GFR | NCT02316821 (TSUBAKI study) | ||
IgAN, CKD associated with type 1 diabetes, FSGS, ADPKD | 2 | Increase in the eGFR | NCT03366337 | ||
Patients with type 2 diabetes and stage 4 CKD | 3 | No reduction in the risk of ESKD or death from cardiovascular causes; Increased rate of cardiovascular events | NCT01351675 (BEACON study) | ||
Alport syndrome | 2/3 | Preservation in eGFR | NCT03019185 (CARDINAL study) | ||
Pirfenidone | TGF-β | FSGS | 2 | Decreased GFR loss; No change in proteinuria | NCT00001959 |
DKD | 1/2 | GFR increased in the pirfenidone 1200-mg/d group | NCT00063583 | ||
DKD | 3 | Unknown | NCT02689778 | ||
GCS-100 | Galectin-3 | CKD | 1 | Unknown | NCT01717248 |
CKD | 2 | Unknown | NCT01843790, NCT02155673 | ||
DKD | 2 | Unknown | NCT02312050 | ||
Apabetalone | BET | Fabry Disease | 1/2 | Unknown | NCT03228940 |
CKD subjects with a history of CVD | 2 | Apabetalone was well tolerated; Favorable effects of apabetalone on ALP and eGFR | Post-hoc analysis of NCT01423188 (SUSTAIN study) and NCT01067820 (ASSURE study) | ||
Patients with CKD and type 2 diabetes | 3 | Apabetalone was associated with a reduced hazard for MACE and heart failure hospitalization | CKD subgroup analysis of NCT02586155 (BETonMACE study) |
